“Our proprietary microbial biomarkers are non-invasive, biologically relevant, and disease-specific.”
MicroSigX’s biomarker discovery platform leverages in-depth metagenomic dataset of human microbiome and in-house proprietary machine learning approaches to identify microbiome signatures targeting different human diseases. The gut microbiome is a valuable source of biologically relevant biomarkers that can be transformed into precise diagnostic and prognostic tools. Clinicians can utilize these non-invasive tools for early disease detection and monitoring to optimize clinical decision and improve patient care.
Turning novel bacteria markers into non-invasive diagnostics
to disrupt the diagnostic landscape of cancer diagnosis. Starting with one of the top killers globally, colorectal cancer, we have identified species-specific bacterial gene markers for early detection of colorectal cancer and adenomas. Our bacteria gene markers can detect colorectal cancer early, when it is most treatable and can also detect adenomas, helping to prevent cancer development.
